Canaccord Genuity Maintains Buy on Immunogen, Raises Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst John Newman maintains a 'Buy' rating on Immunogen (NASDAQ:IMGN) and raises the price target from $23 to $25.
August 04, 2023 | 10:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity maintains a 'Buy' rating on Immunogen and raises the price target from $23 to $25.
The news of Canaccord Genuity maintaining a 'Buy' rating and raising the price target for Immunogen is likely to instill confidence in investors and could potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100